Our Opinion
Cartesian Therapeutics Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
Supporting Evidence:
The company stated in the following report that they exploit animals for product testing.
“MM1S-luc cells were harvested and injected on day 0 at 2 × 106 cells per mouse intravenous (i.v.) into 6–9-week-old male NSG mice (NOD.Cg-PrkdcSCIDIl2rgTM1wJ1/SzJ, Jackson labs). Tumor growth was monitored during the study using bioluminescence imaging (BLI).” Read the full document
Company Description
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Company Website: https://www.cartesiantherapeutics.com